The Journey of Nivolumab

Nivolumab is a fully human IgG4 monoclonal antibody (PD-1 inhibitor,
~146 kDa) that must be administered intravenously — no oral or subcutaneous formulation is approved.
Intravenous infusion provides 100% bioavailability with immediate peak concentrations. Standard dosing
regimens include weight-based dosing (3 mg/kg every 2 weeks) or fixed-dose regimens (240 mg every
2 weeks or 480 mg every 4 weeks). Population PK analysis supports fixed-dose equivalency to weight-
based dosing across the approved dose range. Infusions are delivered over 30 minutes (for approved
dosing) or 60 minutes (in combination with ipilimumab). Infusion-related reactions occur in
approximately 5-20% of patients but are generally mild and manageable with premedication and rate
reduction. A subcutaneous formulation (coformulated with hyaluronidase) is under regulatory
review to reduce clinic time burden.

Nivolumab, as a fully human IgG4 antibody, distributes in a
volume of approximately 8.0 L, reflecting near-exclusive confinement to plasma and interstitial
fluid. The IgG4 subclass was deliberately chosen because it is less capable of complement activation
(CDC) and has reduced Fc-receptor-mediated cell killing (ADCC) compared to IgG1 — appropriate for
an antibody designed to block a receptor rather than kill cells. FcRn on endothelial cells recycles
nivolumab (and endogenous IgG4) from lysosomal degradation, extending its half-life to approximately
27 days. Nivolumab distributes to tumor-infiltrating lymphocytes within tumors through the leaky
tumor microvasculature, engaging exhausted PD-1+ T cells. CNS penetration is poor, though immune
checkpoint blockade at peripheral sites may still enable CNS tumor responses.

PD-1 (programmed death-1, CD279, PDCD1) is a co-inhibitory
immunoreceptor expressed on activated and exhausted T cells, B cells, and NK cells. In the tumor
microenvironment, chronic antigen exposure leads to T cell exhaustion characterized by high PD-1
expression and impaired effector function. Tumor cells upregulate PD-L1 (CD274) via IFN-gamma
signaling from infiltrating T cells (an adaptive immune resistance mechanism). PD-L1 binding to
PD-1 recruits SHP-1 and SHP-2 phosphatases to PD-1's ITSM motifs, dephosphorylating TCR
proximal signaling (Lck, ZAP70, CD3-zeta), reducing TCR-mediated proliferation, cytokine
production, and cytotoxicity. Nivolumab binds PD-1 with high affinity (Kd ~2.6 nM), blocking
both PD-L1 and PD-L2 binding — restoring T cell activation, proliferation, and cytotoxic function.
Unlike pembrolizumab (humanized IgG4), nivolumab is fully human, reducing immunogenicity.
The IgG4 Fc region minimizes Fc effector functions on T cells themselves.

As a fully human protein, nivolumab is catabolized by the ubiquitous
proteolytic pathways for endogenous IgG — no CYP450 enzyme involvement. Pharmacokinetics are
largely linear (proportional to dose) at therapeutic concentrations. Target-mediated drug disposition
(TMDD) occurs at very low concentrations when PD-1 receptor-mediated internalization becomes
relevant, but at clinical doses this is minor. Anti-drug antibodies (ADAs) develop in approximately
11% of patients (nivolumab monotherapy), generally at low titers, and are of uncertain clinical
significance. Unlike small-molecule TKIs, nivolumab has no drug-drug interactions via CYP enzymes.
However, concurrent use of systemic corticosteroids (used to manage immune-related adverse events)
can theoretically dampen anti-tumor T cell responses — an important clinical consideration when
managing irAEs.

Nivolumab is eliminated by protein catabolism throughout the body;
no intact antibody appears in urine or feces. The terminal half-life is approximately 27 days,
similar to pembrolizumab. Clearance is approximately 0.31 L/day. Renal and hepatic impairment do
not require dose adjustment because elimination is independent of these organs. Body weight, PS
status, albumin levels, and tumor burden affect nivolumab clearance (population PK variability).
Steady-state concentrations are achieved at approximately 12 weeks with every-2-week dosing.
The 4-week (480 mg) regimen provides equivalent exposure with equivalent clinical outcomes.
After treatment discontinuation, plasma concentrations become undetectable within approximately
100 days (about 4 half-lives), but immunological memory from expanded tumor-specific T cell
clones may provide durable benefit years beyond drug clearance.

Nivolumab (Opdivo) is approved for melanoma (first anti-PD-1 approval),
NSCLC, renal cell carcinoma, Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial
carcinoma, MSI-H/dMMR colorectal cancer, hepatocellular carcinoma, esophageal cancer, gastric/GEJ
adenocarcinoma, and others. Combination with ipilimumab (anti-CTLA-4) provides synergistic checkpoint
blockade at the cost of increased immune-related toxicity (CheckMate 067: melanoma OS benefit).
PD-L1 expression (TPS/CPS scores) guides patient selection in many indications. Immune-related
adverse events (irAEs) — identical in spectrum to pembrolizumab-associated irAEs — include
pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and myocarditis, managed with
immunosuppression (corticosteroids, infliximab). Some irAEs can be permanent (hypothyroidism,
adrenal insufficiency), requiring lifelong hormone replacement.